GSK Registers A Win For Older People RSV Vaccine – But Awaited Data Will Be Crucial

Prevention Rate Still Undisclosed

 
• By Andrew McConaghie
  
GSK_HQ
GSK is the first of the RSV vaccine competitors to declare a successful Phase III study, but the devil will be in the detail.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D